Skip Nav Destination
Issues
1 March 2016
-
Cover Image
Cover Image
The cover shows a section of a B16 melanoma brain tumor from a mouse treated with a listeria-based cancer vaccine in combination with focal radiation therapy. Hematoxylin and eosin staining demonstrates lymphocytes extravasating from tumor vessels and infiltrating into the tumor mass. For details, see the article by Jackson and colleagues on page 1161 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Molecular Pathways
Perspectives
Cancer Therapy: Clinical
Author Choice
A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
Andrew M. Evens; Sriram Balasubramanian; Julie M. Vose; Wael Harb; Leo I. Gordon; Robert Langdon; Julian Sprague; Mint Sirisawad; Chitra Mani; Jeanne Yue; Ying Luan; Sharon Horton; Thorsten Graef; Nancy L. Bartlett
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
Beata Holkova; Adriana Zingone; Maciej Kmieciak; Prithviraj Bose; Ashraf Z. Badros; Peter M. Voorhees; Rachid Baz; Neha Korde; Hui-Yi Lin; Jin-Qiu Chen; Michelle Herrmann; Liqiang Xi; Mark Raffeld; Xiuhua Zhao; Wen Wan; Mary Beth Tombes; Ellen Shrader; Caryn Weir-Wiggins; Heidi Sankala; Kevin T. Hogan; Austin Doyle; Christina M. Annunziata; Martha Wellons; John D. Roberts; Daniel Sullivan; Ola Landgren; Steven Grant
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial
Michele Reni; Erica Dugnani; Stefano Cereda; Carmen Belli; Gianpaolo Balzano; Roberto Nicoletti; Daniela Liberati; Valentina Pasquale; Marina Scavini; Paola Maggiora; Valeria Sordi; Vito Lampasona; Domenica Ceraulo; Gaetano Di Terlizzi; Claudio Doglioni; Massimo Falconi; Lorenzo Piemonti
Author Choice
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Amita Patnaik; Paul Haluska; Anthony W. Tolcher; Charles Erlichman; Kyriakos P. Papadopoulos; Janet L. Lensing; Muralidhar Beeram; Julian R. Molina; Drew W. Rasco; Rebecca R. Arcos; Claudia S. Kelly; Sameera R. Wijayawardana; Xuekui Zhang; Louis F. Stancato; Robert Bell; Peipei Shi; Palaniappan Kulanthaivel; Celine Pitou; Lynette B. Mulle; Daphne L. Farrington; Edward M. Chan; Matthew P. Goetz
Personalized Medicine and Imaging
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses
Tilak K. Sundaresan; Lecia V. Sequist; John V. Heymach; Gregory J. Riely; Pasi A. Jänne; Walter H. Koch; James P. Sullivan; Douglas B. Fox; Robert Maher; Alona Muzikansky; Andrew Webb; Hai T. Tran; Uma Giri; Martin Fleisher; Helena A. Yu; Wen Wei; Bruce E. Johnson; Thomas A. Barber; John R. Walsh; Jeffrey A. Engelman; Shannon L. Stott; Ravi Kapur; Shyamala Maheswaran; Mehmet Toner; Daniel A. Haber
Association between GWAS-Derived rs966423 Genetic Variant and Overall Mortality in Patients with Differentiated Thyroid Cancer
Michał Świerniak; Anna Wójcicka; Małgorzata Czetwertyńska; Joanna Długosińska; Elżbieta Stachlewska; Wojciech Gierlikowski; Adam Kot; Barbara Górnicka; Łukasz Koperski; Magdalena Bogdańska; Wiesław Wiechno; Krystian Jażdżewski
In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma
Charlotte Lussey-Lepoutre; Alexandre Bellucci; Aurélie Morin; Alexandre Buffet; Laurence Amar; Maxime Janin; Chris Ottolenghi; Franck Zinzindohoué; Gwennhael Autret; Nelly Burnichon; Estelle Robidel; Benjamin Banting; Sébastien Fontaine; Charles-André Cuenod; Paule Benit; Pierre Rustin; Philippe Halimi; Laure Fournier; Anne-Paule Gimenez-Roqueplo; Judith Favier; Bertrand Tavitian
Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients
Peilu Wang; Amir Bahreini; Rekha Gyanchandani; Peter C. Lucas; Ryan J. Hartmaier; Rebecca J. Watters; Amruth R. Jonnalagadda; Humberto E. Trejo Bittar; Aaron Berg; Ronald L. Hamilton; Brenda F. Kurland; Kurt R. Weiss; Aju Mathew; Jose Pablo Leone; Nancy E. Davidson; Marina N. Nikiforova; Adam M. Brufsky; Tadeu F. Ambros; Andrew M. Stern; Shannon L. Puhalla; Adrian V. Lee; Steffi Oesterreich
Cancer Therapy: Preclinical
Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma
Magdalena Klanova; Ladislav Andera; Jan Brazina; Jan Svadlenka; Simona Benesova; Jan Soukup; Dana Prukova; Dana Vejmelkova; Radek Jaksa; Karel Helman; Petra Vockova; Lucie Lateckova; Jan Molinsky; Bokang Calvin Lenyeletse Maswabi; Mahmudul Alam; Roman Kodet; Robert Pytlik; Marek Trneny; Pavel Klener
SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
Kate Lynn J. Bill; Jeannine Garnett; Isabelle Meaux; XiaoYen Ma; Chad J. Creighton; Svetlana Bolshakov; Cedric Barriere; Laurent Debussche; Alexander J. Lazar; Bethany C. Prudner; Lucia Casadei; Danielle Braggio; Gonzalo Lopez; Abbie Zewdu; Hemant Bid; Dina Lev; Raphael E. Pollock
Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Christopher M. Jackson; Christina M. Kochel; Christopher J. Nirschl; Nicholas M. Durham; Jacob Ruzevick; Angela Alme; Brian J. Francica; Jimmy Elias; Andrew Daniels; Thomas W. Dubensky, Jr; Peter Lauer; Dirk G. Brockstedt; Emily G. Baxi; Peter A. Calabresi; Janis M. Taube; Carlos A. Pardo; Henry Brem; Drew M. Pardoll; Michael Lim; Charles G. Drake
Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
Maite Verreault; Charlotte Schmitt; Lauriane Goldwirt; Kristine Pelton; Samer Haidar; Camille Levasseur; Jeremy Guehennec; David Knoff; Marianne Labussière; Yannick Marie; Azra H. Ligon; Karima Mokhtari; Khê Hoang-Xuan; Marc Sanson; Brian M. Alexander; Patrick Y. Wen; Jean-Yves Delattre; Keith L. Ligon; Ahmed Idbaih
Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
Mahadev Rao; Scott M. Atay; Vivek Shukla; Young Hong; Trevor Upham; R. Taylor Ripley; Julie A. Hong; Mary Zhang; Emily Reardon; Patricia Fetsch; Markku Miettinen; Xinmin Li; Cody J. Peer; Tristan Sissung; William D. Figg; Assunta De Rienzo; Raphael Bueno; David S. Schrump
Author Choice
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells
Annamaria Gullà; Maria Teresa Di Martino; Maria Eugenia Gallo Cantafio; Eugenio Morelli; Nicola Amodio; Cirino Botta; Maria Rita Pitari; Santo Giovanni Lio; Domenico Britti; Maria Angelica Stamato; Teru Hideshima; Nikhil C. Munshi; Kenneth C. Anderson; Pierosandro Tagliaferri; Pierfrancesco Tassone
Biology of Human Tumors
Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance
Bin Li; Wen Wen Xu; Xin Yuan Guan; Yan Ru Qin; Simon Law; Nikki Pui Yue Lee; Kin Tak Chan; Pui Ying Tam; Yuk Yin Li; Kwok Wah Chan; Hiu Fung Yuen; Sai Wah Tsao; Qing Yu He; Annie L.M. Cheung
Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma
Bo Hwa Sohn; Jae-Jun Shim; Sang-Bae Kim; Kyu Yun Jang; Soo Mi Kim; Ji Hoon Kim; Jun Eul Hwang; Hee-Jin Jang; Hyun-Sung Lee; Sang-Cheol Kim; Woojin Jeong; Sung Soo Kim; Eun Sung Park; Jeonghoon Heo; Yoon Jun Kim; Dae-Ghon Kim; Sun-Hee Leem; Ahmed Kaseb; Manal M. Hassan; Minse Cha; In-Sun Chu; Randy L. Johnson; Yun-Yong Park; Ju-Seog Lee
Author Choice
Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma
Duncan C. Gilbert; Reem Al-Saadi; Khin Thway; Ian Chandler; Daniel Berney; Rhian Gabe; Sally P. Stenning; Joan Sweet; Robert Huddart; Janet M. Shipley
Elevated Coexpression of KITENIN and the ErbB4 CYT-2 Isoform Promotes the Transition from Colon Adenoma to Carcinoma Following APC loss
Jeong A Bae; Dhong Hyo Kho; Eun Gene Sun; Yoo-Seung Ko; Somy Yoon; Kyung Hwa Lee; Kyu Youn Ahn; Jae Hyuk Lee; Young Eun Joo; Ik Joo Chung; Sug Hyung Lee; Hangun Kim; Kyung Keun Kim
Letter to the Editor
Corrections
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds